Other

Richard Ernest Gilbert

Douglas Kirk Ways

Darren James Kelly

Prudence Ann Hill

Steven James Chadban

David John Nikolic-Paterson

Robert Charles Atkins

Mark Emmanuel Cooper

The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein Ris pyridyl bonded at a carbon atom, R, R, R, Rand Rare each hydrogen, Ris lower alkyl, Ra radical of formula (II): &#x2014;N(R)&#x2014;C(&#x2550;X)&#x2014;(Y)&#x2014;R, wherein Rhydrogen, X is oxo, n is 0 and Ris 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

A method for treating renal dysfunctions is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-&lsqb;N, N&prime;-1,1&prime;-((2&Prime;-ethoxy)-3&prime;&Prime;(O)-4&prime;&Prime;-(N,N-dimethylamino)-butane)-bis-(3,3&prime;-indolyl) &rsqb;-1(H)-pyrrole-2,5-dionehydrochloridesalt.

Therapeutic treatment for renal dysfunction

Growing community of inventors

West St. Kilda, Victoria 3182, Australia

Richard Ernest Gilbert